NASDAQ:VRCA Verrica Pharmaceuticals (VRCA) Stock Price, News & Analysis → Elon Musk’s Final Masterpiece: “X-9840” (From Paradigm Press) (Ad) Free VRCA Stock Alerts $9.15 +0.84 (+10.11%) (As of 06/5/2024 ET) Add Compare Share Share Today's Range$8.25▼$9.2750-Day Range$5.65▼$9.5652-Week Range$2.86▼$11.41Volume261,783 shsAverage Volume179,320 shsMarket Capitalization$388.14 millionP/E RatioN/ADividend YieldN/APrice Target$13.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Verrica Pharmaceuticals alerts: Email Address Verrica Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside47.5% Upside$13.50 Price TargetShort InterestBearish14.90% of Float Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.57) to ($0.83) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.22 out of 5 starsMedical Sector300th out of 904 stocksPharmaceutical Preparations Industry134th out of 428 stocks 3.5 Analyst's Opinion Consensus RatingVerrica Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVerrica Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Verrica Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted14.90% of the float of Verrica Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVerrica Pharmaceuticals has a short interest ratio ("days to cover") of 20.2, which indicates bearish sentiment.Change versus previous monthShort interest in Verrica Pharmaceuticals has recently increased by 6.08%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVerrica Pharmaceuticals does not currently pay a dividend.Dividend GrowthVerrica Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVerrica Pharmaceuticals has received a 75.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Verrica Pharmaceuticals is -0.67. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Verrica Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest5 people have searched for VRCA on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verrica Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders42.60% of the stock of Verrica Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.45% of the stock of Verrica Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verrica Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Verrica Pharmaceuticals are expected to grow in the coming year, from ($1.57) to ($0.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verrica Pharmaceuticals is -5.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verrica Pharmaceuticals is -5.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerrica Pharmaceuticals has a P/B Ratio of 19.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Verrica Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Verrica Pharmaceuticals Stock (NASDAQ:VRCA)Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.Read More VRCA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VRCA Stock News HeadlinesMay 30, 2024 | globenewswire.comVerrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New YorkMay 26, 2024 | americanbankingnews.comVerrica Pharmaceuticals (NASDAQ:VRCA) versus Zoetis (NYSE:ZTS) Critical SurveyMay 15, 2024 | markets.businessinsider.comVerrica Pharma Enters Amendment To License Agreement With Torii PharmaMay 15, 2024 | finance.yahoo.comVerrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common WartsMay 15, 2024 | globenewswire.comVerrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common WartsMay 14, 2024 | msn.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q1 2024 Earnings Call TranscriptMay 14, 2024 | finance.yahoo.comVerrica Pharmaceuticals Inc (VRCA) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verrica Pharmaceuticals on Strong Ycanth Sales and Strategic Growth ProspectsMay 13, 2024 | markets.businessinsider.comStrong Buy Rating for Verrica Pharmaceuticals as Ycanth Launch Exceeds ExpectationsMay 13, 2024 | finanznachrichten.deVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 13, 2024 | finance.yahoo.comVerrica Pharmaceuticals Inc (VRCA) Reports Q1 2024 Results: A Detailed Financial ReviewMay 13, 2024 | globenewswire.comVerrica Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 12, 2024 | markets.businessinsider.comHere's what Wall Street expects from Verrica Pharmaceuticals's earningsMay 11, 2024 | msn.comVerrica Pharmaceuticals to Discuss Q1 Financial Results in Upcoming WebcastMay 9, 2024 | globenewswire.comVerrica Pharmaceuticals to Present at Upcoming Investor ConferencesMay 8, 2024 | globenewswire.comVerrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024May 3, 2024 | seekingalpha.comVRCA Verrica Pharmaceuticals Inc.April 19, 2024 | investing.comVerrica Pharmaceuticals Inc (VRCA)April 4, 2024 | msn.comVerrica Pharmaceuticals to Spotlight Innovations at Needham Healthcare ConferenceApril 3, 2024 | finance.yahoo.comStrong week for Verrica Pharmaceuticals (NASDAQ:VRCA) shareholders doesn't alleviate pain of three-year lossApril 2, 2024 | globenewswire.comVerrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 31, 2024 | msn.comVerrica Pharmaceuticals Secures Key FDA Designation for YCANTH, Enhancing Market ProtectionMarch 28, 2024 | finanznachrichten.deVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDAMarch 27, 2024 | msn.comVerrica Pharma gains as FDA lists Ycanth in Orange BookMarch 26, 2024 | markets.businessinsider.comVerrica Pharmaceuticals: YCANTH Granted NCE Status By FDA - Quick FactsSee More Headlines Receive VRCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today6/05/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VRCA CUSIPN/A CIK1660334 Webwww.verrica.com Phone(434) 453-3300FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$13.50 High Stock Price Target$16.00 Low Stock Price Target$10.00 Potential Upside/Downside+47.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,000,000.00 Net Margins-905.83% Pretax Margin-905.83% Return on Equity-229.26% Return on Assets-88.77% Debt Debt-to-Equity Ratio29.58 Current Ratio3.17 Quick Ratio3.04 Sales & Book Value Annual Sales$5.12 million Price / Sales75.81 Cash FlowN/A Price / Cash FlowN/A Book Value$0.47 per share Price / Book19.47Miscellaneous Outstanding Shares42,420,000Free Float24,349,000Market Cap$388.14 million OptionableOptionable Beta1.77 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Ted White (Age 59)President, CEO & Director Comp: $914.68kMr. Christopher G. Hayes (Age 60)Chief Legal Officer, Secretary, Chief Compliance Officer & General Counsel Comp: $607.38kMr. Joe Bonaccorso (Age 60)Chief Commercial Officer Comp: $635.38kMr. P. Terence KohlerChief Financial OfficerDr. Gary Goldenberg M.D. (Age 47)Chief Medical Officer Comp: $553.03kMr. Eugene ScavolaExecutive Vice President of Technical OperationsDr. Bradley J. Catalone MBAPh.D., Head of Drug DevelopmentMore ExecutivesKey CompetitorsNature's Sunshine ProductsNASDAQ:NATRVerastemNASDAQ:VSTMChimerixNASDAQ:CMRXFortress BiotechNASDAQ:FBIOSpyre TherapeuticsNASDAQ:SYREView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 7,609 shares on 5/10/2024Ownership: 2.991%BNP Paribas Financial MarketsSold 29,646 shares on 5/1/2024Ownership: 0.024%Perceptive Advisors LlcBought 126,116 shares on 12/28/2023Total: $892,901.28 ($7.08/share)Perceptive Advisors LlcBought 54,652 shares on 12/26/2023Total: $354,691.48 ($6.49/share)Perceptive Advisors LlcBought 200,000 shares on 12/21/2023Total: $1.23 M ($6.17/share)View All Insider TransactionsView All Institutional Transactions VRCA Stock Analysis - Frequently Asked Questions Should I buy or sell Verrica Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VRCA shares. View VRCA analyst ratings or view top-rated stocks. What is Verrica Pharmaceuticals' stock price target for 2024? 4 Wall Street research analysts have issued 1-year target prices for Verrica Pharmaceuticals' stock. Their VRCA share price targets range from $10.00 to $16.00. On average, they expect the company's share price to reach $13.50 in the next twelve months. This suggests a possible upside of 47.5% from the stock's current price. View analysts price targets for VRCA or view top-rated stocks among Wall Street analysts. How have VRCA shares performed in 2024? Verrica Pharmaceuticals' stock was trading at $7.32 at the start of the year. Since then, VRCA stock has increased by 25.0% and is now trading at $9.15. View the best growth stocks for 2024 here. When is Verrica Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our VRCA earnings forecast. How were Verrica Pharmaceuticals' earnings last quarter? Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) released its earnings results on Monday, May, 13th. The company reported ($0.44) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.10. The company earned $3.83 million during the quarter, compared to analysts' expectations of $2.70 million. Verrica Pharmaceuticals had a negative trailing twelve-month return on equity of 229.26% and a negative net margin of 905.83%. What ETF holds Verrica Pharmaceuticals' stock? Simplify Propel Opportunities ETF holds 106,661 shares of VRCA stock, representing 0.92% of its portfolio. What other stocks do shareholders of Verrica Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Verrica Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Novan (NOVN), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), CBL & Associates Properties (CBL), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI) and Aeterna Zentaris (AEZS). When did Verrica Pharmaceuticals IPO? Verrica Pharmaceuticals (VRCA) raised $75 million in an IPO on Friday, June 15th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen served as the underwriters for the IPO. Who are Verrica Pharmaceuticals' major shareholders? Verrica Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.99%) and BNP Paribas Financial Markets (0.02%). Insiders that own company stock include Christopher G Hayes, Joe Bonaccorso, John A Stalfort III, Paul B Manning, Perceptive Advisors Llc and Ted White. View institutional ownership trends. How do I buy shares of Verrica Pharmaceuticals? Shares of VRCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VRCA) was last updated on 6/5/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s Final Masterpiece: “X-9840”The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Ju...Paradigm Press | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored[Webinar] Understanding Covered CallsDiscover the details of this option-selling strategy.OIC | SponsoredWhat’s Pelosi Buying Now?They Make the Top Investors Look Like Amateurs They beat the market for three years straight… avoided some ...Altimetry | SponsoredNext President (Not Trump. Not Biden.)Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | SponsoredClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an eff...Crypto Swap Profits | SponsoredWarren Buffett & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verrica Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.